Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Inclusion Criteria: * Patients with histopathologic diagnosis of salivary gland carcinoma * The tumor tissues were subjected to HER2/NTRK/AR/TROP-2 immunohistochemical staining. * ECOG physical status 0 or 1 score in the 3 days before the first medication of the study treatment; * Age 18 or older - no upper limit; * Life expectancy is more than 3 months; ⑥Have at least one measurable lesion according to RECIST1.1 standards; ⑦Women of childbearing age must have a negative pregnancy test within 7 days before the first medication, and agree to receive the necessary contraceptive measures; ⑧The patient must have adequate liver, kidney, bone marrow, heart and lung and other organ functions: ⑨Understanding and voluntarily signing informed consent prior to performing any research-related evaluation/operation; ⑩Ability to comply with research visit schedules and other programmatic requirements. Exclusion Criteria: * Known hypersensitivity or delayed anaphylaxis to any agents in this trial; * Major surgery had been performed within 4 weeks prior to the start of the study and did not fully recover; * Have received a live vaccine within 4 weeks before the start of the study or plan to receive any vaccine during the study period ; * To study the occurrence of arterial/venous thrombosis events within 6 months before medication; * Major cardiovascular diseases; * Is suffering from uncontrolled sy…